<DOC>
	<DOCNO>NCT00057330</DOCNO>
	<brief_summary>The primary purpose study see herpes vaccine may prevent genital herpes disease woman infect . The study enroll approximately 7550 healthy woman . These woman randomly assign 1 2 possible study group : herpes vaccine ( experimental group ) hepatitis A vaccine ( control group ) . Participants receive assign vaccine 0 , 1 , 6 month . Participants 9 schedule study visit additional unscheduled visit evaluation herpes suspect . Participants involve study related procedure 20 month .</brief_summary>
	<brief_title>HerpeVac Trial Young Women</brief_title>
	<detailed_description>This study double-blind , randomize , control Phase III trial ass prophylactic efficacy safety gD-Alum/MPL vaccine prevention genital herpes disease young woman herpes simplex virus ( HSV ) -1 -2 seronegative . The primary efficacy objective evaluate vaccine efficacy prevention genital herpes disease cause HSV-1 and/or HSV-2 month 2 20 healthy adult woman initially HSV-1 HSV-2 seronegative . The secondary efficacy objective : evaluate vaccine efficacy prevention genital herpes disease cause HSV-1 and/or HSV-2 occur month 7 20 ; evaluate vaccine efficacy prevention HSV-2 infection month 2 20 ; evaluate vaccine efficacy prevention HSV-2 infection occur month 7 20 . The study enroll approximately 7,550 woman , age 18-30 year . Participants randomize 1 2 possible study group : candidate vaccine ; control vaccine ( hepatitis A vaccine ) . The study duration subject approximately 20 month . Study procedures include 9 schedule study visit ( include screen visit ) additional unscheduled visit evaluation suspect herpes disease episode . Three dos vaccine control administer intramuscularly non-dominant deltoid 0 , 1 , 6 month schedule . Subjects attend clinic visit screen , month 2 , 7 , 12 , 16 , 20 . In subject present suspect herpes disease month 17 20 , additional visit collect serum sample schedule 3 month evaluation suspect genital herpes .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>A female , include , 18 30 year age time first vaccination . Written inform consent obtain subject . Free obvious health problem establish medical history clinical examination enter study . Seronegative HSV1 HSV2 Western blot . Subject must nonchildbearing potential , i.e . either surgically sterilize , child bear potential , must use highly effective method birth control ( e.g. , intrauterine contraceptive device ; oral contraceptive ; diaphragm condom combination contraceptive jelly , cream foam ; Norplant® ; DepoProvera® ; contraceptive skin patch cervical ring ) 30 day prior vaccination , negative urine pregnancy test must agree continue precaution two month completion vaccination series . A subject investigator believe comply requirement protocol ( e.g . completion memory aid/diary card , return followup visit , accessible phone pager , able selfsample plan move study area ) . Pregnant nursing female . Clinical sign symptom current orolabial , genital nongenital HSV disease , swell , papule , vesicle , pustule , ulcer , crust , fissure , erythema , discharge , pain , burning , itch , tingle dysuria . Previous vaccination herpes . Previous administration monophosphoryl lipid A ( MPL ) adjuvant ( vaccine currently license USA contain ) . History confirm orolabial , genital nongenital HSV disease infection . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration nonstudy vaccine within 30 day first dose study vaccine follow exception : Administration routine Meningococcal , Hepatitis B , inactivate Influenza , Diphtheria/Tetanus vaccine 8 day first dose study vaccine allow . History allergic disease reaction likely exacerbate component study vaccine , e.g . aluminum , MPL , alumMPL , 2phenoxyethanol neomycin . Any confirm suspected immunosuppressive immunodeficient condition include , human immunodeficiency virus ( HIV ) infection . Acute chronic , clinically significant ( unresolved , require ongoing medical management medication , etc . ) pulmonary , cardiovascular , hepatic renal function abnormality , determine medical history physical examination . Acute disease time enrollment ( defer vaccination subject recovers ) . Acute disease define presence moderate severe illness without fever . Study vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness . Oral temperature great equal 99.5º F ( great equal 37.5º C ) / axillary temperature great equal 99.5º ( great equal 37.5º C ) / tympanic temperature oral set great equal 99.5º F ( great equal 37.5º C ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . ( For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow . ) Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Recent history chronic alcohol consumption ( define 5 oz ethanol [ absolute alcohol ] per day ) and/or drug abuse . History sexually transmit infection within 30 day precede first dose study vaccine .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>